Milestone Pharmaceuticals continues to face challenges as its CARDAMYST drug shows weak differentiation and poor market adoption against cheaper generics. In Q2, revenue was only $559K from over 1,200 prescriptions, hindered by heavy discounting and limited insurance coverage, with just 20% of the PSVT market covered. Financial health is worsening, with cash at $170M, a $39M burn in the first half, liabilities doubling to $163M, and equity dropping to $18M due to high expenses and growing royalty debts. Although expanding coverage and Medicare access might improve pricing, volume and adoption remain low, and future costs will pressure margins further.
Can-Am has introduced its 2027 range of side-by-side vehicles (SSV) and all-terrain vehicles (ATV), featuring the new Defender XU model with utility-focused features and a redesigned Defender HD10 with a triple-cylinder engine. All Maverick R models ...
IBM's stock declined 9% following a sharp 42% drop in mainframe sales in Q2 2026, causing investor concern. Despite this, the stock appears fairly valued rather than a bargain. IBM's growth now relies heavily on its software segment, which makes up 4...
Centrifuge, a platform for tokenizing real-world assets (RWAs) on blockchain, has seen a 300% growth in tokenized assets, reaching nearly $4 billion. This growth contrasts with the broader DeFi market, which has contracted due to speculative token dy...
The gap between diesel prices and crude oil costs, known as the "crack spread," has hit a record $102.20 per barrel due to global supply disruptions from conflicts in Iran and Ukraine and peak seasonal demand. This surge is expected to drive up food ...
Uniswap founder Hayden Adams highlights the potential of automated market makers (AMMs) for trading tokenized stocks, supported by $33 million in trading volume on Robinhood-issued tokenized stocks via Uniswap. AMMs are well-suited for equities becau...
